IGF-DES — 2mg

IGF-DES, also known as des(1-3)IGF-1, is a truncated analog of Insulin-like Growth Factor 1 (IGF-1). This potent research peptide is structurally distinct from its parent molecule, consisting of 67 amino acids instead of the full 70. The designation 'des(1-3)' signifies the deliberate removal of the N-terminal tripeptide sequence: Glycine-Proline-Glutamate. This specific modification is the primary reason for its significant interest within the scientific community, as it profoundly alters the peptide's biochemical behavior and interaction with key regulatory proteins in biological systems.

The full 70-amino acid sequence of human IGF-1 is well-characterized, and IGF-DES represents a precision-engineered variant. The removal of the initial three amino acids drastically reduces its affinity for the family of Insulin-like Growth Factor-Binding Proteins (IGFBPs). In typical physiological models, IGFBPs sequester IGF-1, modulating its bioavailability and half-life. By evading this binding mechanism, IGF-DES exhibits substantially increased bioavailability to interact directly with its target receptor, the IGF-1 receptor (IGF-1R). This characteristic makes it a valuable tool for researchers studying cellular pathways where potent and direct activation of the IGF-1R is desired, without the confounding variable of IGFBP modulation.

This enhanced potency and direct action allow for the investigation of cellular signaling cascades with greater precision. Researchers utilize IGF-DES in a variety of *in vitro* and *in vivo* models to explore processes such as cell proliferation, differentiation, and survival. Its application spans fields from muscle physiology, where it is used to study myogenesis and protein synthesis, to neuroscience, where its neuroprotective potential is examined. The unique properties of IGF-DES provide a distinct advantage for studies aiming to isolate the effects of direct IGF-1 receptor agonism.

At Nexa Peptides, our IGF-DES is synthesized for research purposes only, adhering to the highest standards of purity and quality. It is a critical compound for laboratories investigating the intricate roles of the IGF signaling axis in cellular growth, metabolic regulation, and tissue repair. Its use is strictly intended for qualified researchers conducting preclinical studies. This product is not for human consumption or therapeutic use.

The mechanism of action of IGF-DES is centered on its potent and specific interaction with the Insulin-like Growth Factor 1 Receptor (IGF-1R), a transmembrane receptor tyrosine kinase. The defining feature of IGF-DES, its N-terminal truncation, is key to its enhanced biological activity observed in research models. This modification reduces its binding affinity for Insulin-like Growth Factor-Binding Proteins (IGFBPs) by several orders of magnitude compared to full-length IGF-1. IGFBPs normally function as carrier proteins that sequester IGF-1 in the extracellular matrix and circulation, thereby regulating its access to the IGF-1R. By largely bypassing this sequestration, a greater concentration of free IGF-DES is available to bind and activate the IGF-1R, leading to a more potent cellular response in many experimental systems.

Upon binding to the alpha subunits of the IGF-1R, IGF-DES induces a conformational change that triggers the autophosphorylation of specific tyrosine residues on the intracellular beta subunits of the receptor. This phosphorylation event creates docking sites for various intracellular substrate proteins, primarily the Insulin Receptor Substrate (IRS) family (IRS-1, IRS-2) and Shc (Src homology 2 domain-containing protein). The recruitment and subsequent phosphorylation of these adaptor proteins initiate two principal downstream signaling cascades critical to cellular function.

The first major pathway is the Phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway, which is central to cell growth, proliferation, and survival. Phosphorylated IRS proteins recruit and activate PI3K, which in turn catalyzes the conversion of phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 acts as a second messenger, recruiting and facilitating the activation of protein kinase B (Akt). Activated Akt is a crucial signaling hub that promotes cell survival by phosphorylating and inactivating pro-apoptotic factors like BAD and the FOXO family of transcription factors. Furthermore, Akt activates the mammalian Target of Rapamycin Complex 1 (mTORC1), a master regulator of protein synthesis, which drives cellular growth and anabolism by phosphorylating downstream targets such as S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1).

The second critical pathway initiated by IGF-1R activation is the Ras/Raf/MEK/ERK (also known as the MAPK) pathway. This cascade is typically initiated following the recruitment and phosphorylation of Shc. This leads to the activation of the small GTPase Ras, which subsequently triggers a phosphorylation cascade involving Raf, MEK, and finally the Extracellular signal-Regulated Kinases (ERK1/2). The MAPK pathway is primarily involved in mitogenesis, regulating gene expression related to cell proliferation and differentiation. The dual activation of both the PI3K/Akt and MAPK pathways allows IGF-DES to be a powerful tool in research models for studying a wide range of cellular processes, from anabolic effects in muscle and bone cells to neuroprotective actions in neuronal cultures. Its potent, direct agonism of the IGF-1R makes it an invaluable compound for dissecting these complex signaling networks.

IGF-DES is a highly valued compound in preclinical research due to its enhanced potency and direct action on the IGF-1 receptor. Its unique ability to bypass regulation by IGFBPs makes it a precise tool for investigating the direct consequences of IGF-1R signaling in various biological contexts. Laboratory research applications span multiple disciplines, including endocrinology, cell biology, and regenerative medicine, utilizing a range of *in vitro* and *in vivo* models.

One of the most prominent areas of study is in muscle physiology and myogenesis. Researchers use IGF-DES in cell culture models, such as C2C12 myoblasts, to investigate its effects on muscle cell proliferation, differentiation, and hypertrophy. Studies have explored its capacity to stimulate protein synthesis and inhibit protein degradation through the robust activation of the PI3K/Akt/mTOR pathway. In animal models, IGF-DES has been investigated for its potential to mitigate muscle atrophy under catabolic conditions, such as those induced by immobilization or glucocorticoids, providing a model for studying mechanisms of muscle wasting and recovery.

In the field of metabolic research, IGF-DES is studied for its effects on glucose homeostasis and insulin sensitivity. Given the structural and functional homology between the IGF-1 receptor and the insulin receptor, IGF-DES is used to explore insulin-like effects on glucose uptake in peripheral tissues like skeletal muscle and adipose tissue. Preclinical studies in rodent models of metabolic dysfunction or diabetes investigate how potent IGF-1R activation influences systemic glucose metabolism, glycogen synthesis, and lipid metabolism. These studies help elucidate the distinct and overlapping roles of the IGF-1 and insulin signaling pathways.

Furthermore, IGF-DES is a subject of investigation in tissue repair and wound healing. Its potent mitogenic and anti-apoptotic properties are examined in models of injury to various tissues, including skin, bone, and connective tissues. For instance, researchers may apply IGF-DES to fibroblast or osteoblast cultures to study its impact on cell proliferation and extracellular matrix protein synthesis. In animal models of bone fractures or dermal wounds, its local application is investigated to understand its role in accelerating cellular regeneration and improving the quality of tissue repair. These studies provide fundamental insights into the growth-factor-mediated processes that govern healing.

Neuroscience represents another critical area of research for IGF-DES. The IGF-1 signaling pathway is known to be crucial for neuronal development, survival, and plasticity. Researchers utilize IGF-DES in primary neuronal cultures to study its neuroprotective effects against various insults, such as oxidative stress or excitotoxicity. In animal models of ischemic injury or neurodegenerative conditions, IGF-DES is investigated for its potential to promote neuronal survival and synaptic health. These preclinical investigations aim to dissect the molecular mechanisms by which potent IGF-1R activation can support the central and peripheral nervous systems. All such applications are strictly confined to laboratory research settings. For Research Use Only.